The short version of certificate of analysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-11. Anything still debated is marked as such rather than presented as settled.
Handling and storage influence measured purity, and peptides can oxidize, deamidate, aggregate, or adsorb to surfaces over time. Lyophilized powders stored at -20 °C or lower are generally more stable than solutions, though some sequences require different conditions. Repeated freeze-thaw cycles can promote aggregation and loss, so testing after storage checks whether purity has changed. Stability-indicating methods compare stressed and unstressed samples to detect degradation pathways. Light exposure and pH can also accelerate modification.
Solid-phase peptide synthesis can produce truncated sequences when coupling reactions fail. Deletion peptides lack one or more internal residues, while truncation peptides end prematurely. Side reactions include aspartimide formation, oxidation of methionine, and aggregation during chain assembly. Crude synthetic peptides therefore contain target peptide plus related impurities, counterions, residual solvents, and water. Purification by preparative chromatography reduces these impurities but does not remove every closely related species, including some that differ by a single amino acid.
Quality control specifications for peptides typically include appearance, identity, purity by RP-HPLC, water content, counterion content, and residual trifluoroacetic acid. Karl Fischer titration measures water, while ion chromatography or elemental analysis can quantify counterions. Purity specifications may be set at 95% or 98% area percent, but the appropriate threshold depends on the application. For research reagents, a lower purity may be acceptable if identity is confirmed. For assays sensitive to impurities, higher purity and orthogonal testing are often required.
Regulatory and accreditation expectations depend on the peptide's intended use. Research reagents may be tested with in-house methods, while pharmaceutical development follows validated procedures and pharmacopeial chapters where applicable. Method validation commonly examines accuracy, precision, specificity, linearity, range, and limits of detection and quantitation. Laboratories accredited to ISO/IEC 17025 must document competence, equipment calibration, and uncertainty. Comparing purity results across laboratories remains difficult because different columns, gradients, detection wavelengths, and integration rules can change reported values; open questions include how best to standardize impurity identification and reporting for diverse peptide products.
Quality control for peptides places purity testing within a documented system that includes specifications, test methods, and acceptance criteria. A certificate of analysis typically reports appearance, chromatographic purity, mass confirmation, and storage conditions. System suitability checks, blank injections, and reference standards help ensure that an analytical run is valid. Traceability requires records of sample preparation, instrument settings, and data processing. No single purity threshold applies to all peptides or uses, so specifications are set according to the intended application and risk assessment.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | ≥95% by RP-HPLC | Common for research-grade material; some assays require 98% or higher. |
| Water content | 5–10% w/w | Lyophilized peptides retain moisture; Karl Fischer titration measures it. |
| Counterion | Trifluoroacetate or acetate | Counterion identity affects mass balance and assay compatibility. |
| Storage temperature | -20 °C or lower | Store desiccated and protected from light; avoid repeated freeze-thaw. |
| Common impurity | Deletion or truncation peptide | Similar sequence complicates chromatographic separation. |
Mass spectrometry provides an identity check that complements chromatographic purity. Electrospray ionization or matrix-assisted laser desorption/ionization measures the mass-to-charge ratio of intact peptides. A match to the expected molecular mass supports correct sequence length and terminal groups. Mass accuracy alone does not prove that every peak in a liquid chromatogram is the target peptide. It also does not directly quantify how much water or counterion remains in a lyophilized powder.
Orthogonal methods reduce the chance that a single technique misses an impurity. Capillary electrophoresis separates by charge-to-size ratio and can resolve variants that co-elute under one set of HPLC conditions. Amino acid analysis reports composition after hydrolysis and confirms the presence of expected residues. Karl Fischer titration measures water content, while ion chromatography can quantify counterions. No single number captures all aspects of sample quality, so reports often combine several measurements.
Peptide purity testing uses separation methods to estimate the proportion of a sample that corresponds to the target sequence. Reverse-phase high-performance liquid chromatography is the most common technique, separating peptides by hydrophobicity on a nonpolar column. Ultraviolet detection at 214 nm records peptide bonds and aromatic residues. The resulting chromatogram is reported as area percent, which reflects relative absorbance rather than absolute mass. This distinction matters because water, counterions, and residual solvents do not appear in the peptide peak.
Reverse-phase high-performance liquid chromatography is the most common primary method for peptide purity testing. The peptide mixture passes through a hydrophobic stationary phase, and components elute according to differences in hydrophobicity. A mobile phase of water and acetonitrile, often with trifluoroacetic acid as an ion-pairing agent, improves peak shape and retention. Ultraviolet detection at 214 nm records the peptide backbone absorbance, and the main peak area is divided by the total peak area to give an area-percent purity value.
Other chromatographic modes provide complementary information that reverse-phase separation may not capture. Ion-exchange chromatography separates peptides by net charge and can resolve deamidated, oxidized, or truncated variants that co-elute under hydrophobic conditions. Size-exclusion chromatography detects aggregates and higher-order oligomers, which are often invisible in reverse-phase assays. Chiral chromatography can quantify D-amino acid epimers when stereochemical purity matters. Because each mode uses a different separation principle, a single purity number from one method cannot describe all possible impurities.
=== Spiritual === LSD can catalyze intense spiritual experiences and is thus considered an entheogen. Some users have reported out of body experiences. In 1966, Timothy Leary established the League for Spiritual Discovery with LSD as its sacrament. Stanislav Grof has written that religious and mystical experiences observed during LSD sessions appear similar to descriptions in sacred scriptures of great religions of the world and the texts of ancient civilizations.
As early as 520 BCE, Jain philosophy, a non-creationist philosophy based on the teachings of Mahavira, stated that the universe and its constituents such as matter cannot be destroyed or created. The Jain text Tattvarthasutra (2nd century CE) states that a substance is permanent, but its modes are characterised by creation and destruction. An important idea in ancient Greek philosophy was that "Nothing comes from nothing", so that what exists now has always existed: no new matter can come into existence where there was none before. An explicit statement of this, along with the further principle that nothing can pass away into nothing, is found in Empedocles (c. 4th century BCE): "For it is impossible for anything to come to be from what is not, and it cannot be brought about or heard of that what is should be utterly destroyed." A further principle of conservation was stated by Epicurus around the 3rd century BCE, who wrote in describing the nature of the Universe that "the totality of things was always such as it is now, and always will be".
== Medical relevance == Genetic PGLYRP2 variants or changed expression of PGLYRP2 are associated with some diseases. Patients with inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, have significantly more frequent missense variants in PGLYRP2 gene (and also in the other three PGLYRP genes) than healthy controls. These results suggest that PGLYRP2 protects humans from these inflammatory diseases, and that mutations in PGLYRP2 gene are among the genetic factors predisposing to these diseases. PGLYRP2 variants are also associated with esophageal squamous cell carcinoma and Parkinson's disease. Increased serum PGLYRP2 levels are present in patients with systemic lupus erythematosus (and correlate with disease activity index, renal damage, and abnormal lipid profile), chronic hepatitis B virus infection, myocardial infarction, and coronary artery disease (and correlate with the severity of the disease). Decreased expression of PGLYRP2 is found in HIV-associated tuberculosis, drug-sensitive tuberculosis, Lyme disease, hepatocellular carcinoma, and polyarteritis nodosa. Autoantibodies to PGLYRP2 are significantly increased in patients with rheumatoid arthritis.
== Side effects == The adverse effects include drowsiness, dizziness, confusion, constipation, anxiety, nausea, blurred vision, restlessness, decreased coordination, dry mouth, shallow breathing, hallucinations, irritability, problems with memory or concentration, tinnitus and trouble urinating. Chlorphenamine produces less sedation than other first-generation antihistamines. A large study on people 65 years old or older linked the development of Alzheimer's disease and other forms of dementia to the "higher cumulative" use of chlorphenamine and other first-generation antihistamines, due to their anticholinergic properties. Chlorphenamine is rated as a "high burden" anticholinergic by experts on a semi-subjective scale. This is inconsistent with the in vitro experiments showing low affinity to muscarinic acetylcholine receptors (see below).
The positive value shows that No2+ is more stable than No3+ and that No3+ is a good oxidizing agent. While the quoted values for the E°(No2+→No0) and E°(No3+→No0) vary among sources, the accepted standard estimates are −2.61 and −1.26 V. It has been predicted that the value for the E°(No4+→No3+) couple would be +6.5 V. The Gibbs energies of formation for No3+ and No2+ are estimated to be −342 and −480 kJ/mol, respectively.
Sources: en.wikipedia.org
HCl(aq) + NaOH(aq) → H2O(l) + NaCl(aq) Neutralization is the basis of titration, where a pH indicator shows equivalence point when the equivalent number of moles of a base have been added to an acid. It is often wrongly assumed that neutralization should result in a solution with pH 7.0, which is only the case with similar acid and base strengths during a reaction. Neutralization with a base weaker than the acid results in a weakly acidic salt. An example is the weakly acidic ammonium chloride, which is produced from the strong acid hydrogen chloride and the weak base ammonia. Conversely, neutralizing a weak acid with a strong base gives a weakly basic salt (e.g., sodium fluoride from hydrogen fluoride and sodium hydroxide).
Many drugs are metabolised by a set of liver enzymes called CYP450s. The activity of these enzymes would determine the rate of pro-drug activation and the rate of inactivation of active drugs. For example, warfarin, a commonly used anticoagulant drug in atrial fibrillation, is metabolised by an enzyme called CYP2C9. Phenytoin, a CYP2C9 inducer, would increase its activity and the rate of warfarin breakdown, thereby reducing its efficacy. Patients should avoid the co-administration of warfarin and phenytoin. In cases where both drugs must be used together, warfarin dosing may be titrated up to cope with the reduced efficacy. The kidney excretes most drugs through urine. Since urine is weakly alkaline in nature, weakly acid drugs would ionise in urine, making it difficult for them to be reabsorbed. Therefore, in cases of aspirin (weak acid) toxicity, injecting intravenous sodium bicarbonate could increase urine pH, thereby increasing the excretion of aspirin through urine. A similar approach can be used in other weakly acidic drug toxicity.
== History == Two main studies showed that treosulfan is at least as effective as busulfan, another medicine used to prepare people for haematopoietic stem cell transplantation. In one of the studies, involving 570 adults with acute myeloid leukaemia (a blood cancer) or myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced), 64% of patients given treosulfan (with fludarabine) had a successful transplant and were alive and disease-free after 2 years, compared with 51% of patients given busulfan (with fludarabine). In an additional study in 70 children with blood cancers, 99% of children given treosulfan (with fludarabine) were alive three months after their transplant. Efficacy was evaluated in MC-FludT.14/L Trial II (NCT00822393), a randomized active-controlled trial comparing treosulfan to busulfan with fludarabine as a preparative regimen for allogeneic transplantation. Eligible patients included adults 18 to 70 years old with AML or MDS, Karnofsky performance status ≥ 60%, and age ≥ 50 years or hematopoietic cell transplantation comorbidity index [HCTCI] score > 2. There were 570 patients randomized to treosulfan (n=280) or busulfan (n=290).
=== Proteomics === Screens for biologically relevant protein-protein interactions have been performed using Tandem Affinity Purification (TAP) with the SBP-Tag and Protein A, for interaction proteomics and transcription factor complexes with the SBP-Tag and Protein G, for proteins that interact with the Dengue Virus protein DENV-2 NS4A with the SBP-Tag and the Calmodulin Tag. and for proteins that interact with protein phosphatase 2A (PP2A) with the SBP-Tag and the hemagglutinin (HA)-tag.
Sources: en.wikipedia.org
No. Purity testing measures chemical composition and does not assess biological activity, sterility, or endotoxin levels. Functional performance must be tested in the intended assay.
Water adds mass and can affect concentration calculations. A peptide labeled 95% pure may contain water and counterions that reduce the actual peptide content.
Identity can be checked by mass spectrometry, and purity by RP-HPLC. Store according to supplier instructions and retest if experimental performance changes.
A certificate of analysis reports test results, methods, and specifications for a peptide lot. It often includes appearance, purity by chromatography, mass confirmation, and storage recommendations. It supports quality assessment but does not by itself guarantee suitability for every application.